China SXT Pharmaceuticals surged 19.72% in intraday trading, with the company announcing a planned 9000 million new share issuance in June 2025 to raise funds, alongside its focus on traditional Chinese medicine (TCM) product development and a client base spanning 57 pharmaceutical companies, 14 chain pharmacies, and 16 hospitals across five provinces.
Comments
No comments yet